Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Unknown 2Completed 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Dermatologic 2Breast 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1Breast Neoplasms 1

Interventions

Trastuzumab 379Paclitaxel 369Cyclophosphamide 338Docetaxel 314Capecitabine 198Doxorubicin 196Letrozole 184Tamoxifen 154Carboplatin 153Fulvestrant 136Bevacizumab 129Anastrozole 120exemestane 119Lapatinib 117Epirubicin 116Gemcitabine 112Radiotherapy 107palbociclib 94Exercise 87Fluorouracil 83Vinorelbine 82Surveys and Questionnaires 81pertuzumab 77Albumin-Bound Paclitaxel 76Filgrastim 71130-nm albumin-bound paclitaxel 64pembrolizumab 63Everolimus 59Cisplatin 59eribulin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Drug Evaluation × Breast × Clear all
NCT05054751 2024-10-10

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

Genor Biopharma Co., Ltd.

Phase 3 Completed
275 enrolled
Breast

Breast Neoplasms

NCT03236974 2020-02-06

D6090C00002

AstraZeneca

Phase 1 Completed
49 enrolled
Breast

Postmenopausal Women With ER+ HER2- Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡